Zanubrutinib (Brukinsa®)

Assessment Status Rapid review complete
HTA ID 21044
Drug Zanubrutinib
Brand Brukinsa®
Indication Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy
Assessment Process
Rapid review commissioned 11/10/2021
Rapid review completed 16/11/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013